Regional Analysis The GLP-1 receptor agonist market is segmented geographically across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
Each plug included the entire cartilage layer and a piece of subchondral bone below the cartilage
These therapeutic agents contribute to improvements in key cardiovascular risk factors, including reductions in body weight, blood pressure, and glycaemic variability, all of which are independently associated with decreased cardiovascular risk [4, 5]
In addition to their significant A1C-lowering effects, the landmark clinical trials for these respective agents found substantial appetite suppression, less feeling of "reward" after eating, and subsequent weight loss